110 related articles for article (PubMed ID: 16037415)
1. Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats.
Sobol E; Yagen B; Winkler I; Britzi M; Gibson D; Bialer M
Drug Metab Dispos; 2005 Oct; 33(10):1538-46. PubMed ID: 16037415
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug.
Sobol E; Yagen B; Steve White H; Wilcox KS; Lamb JG; Pappo O; Wlodarczyk BJ; Finnell RH; Bialer M
Neuropharmacology; 2006 Sep; 51(4):933-46. PubMed ID: 16890251
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of the pharmacokinetics, brain uptake and metabolism of E121, an antiepileptic enaminone ester, in rats.
Khurana M; Salama NN; Scott KR; Nemieboka NN; Bauer KS; Eddington ND
Biopharm Drug Dispos; 2003 Dec; 24(9):397-407. PubMed ID: 14689468
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats.
Bohlooli S; Keyhanfar F; Mahmoudian M
Biopharm Drug Dispos; 2004 May; 25(4):187-91. PubMed ID: 15108221
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.
Mamidi RN; Mannens G; Annaert P; Hendrickx J; Goris I; Bockx M; Janssen CG; Kao M; Kelley MF; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):566-75. PubMed ID: 17220243
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of verproside after intravenous and oral administration in rats.
Park EJ; Lee HS; Oh SR; Lee HK; Lee HS
Arch Pharm Res; 2009 Apr; 32(4):559-64. PubMed ID: 19407974
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
Chan S; Edwards SR; Wyse BD; Smith MT
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of florfenicol and its metabolite, florfenicol amine, in dogs.
Park BK; Lim JH; Kim MS; Hwang YH; Yun HI
Res Vet Sci; 2008 Feb; 84(1):85-9. PubMed ID: 17570454
[TBL] [Abstract][Full Text] [Related]
10. Gestational age dependency in the prenatal toxicity and in the disposition kinetics of the novel anticonvulsant HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) after subcutaneous administration in pregnant rats.
Gómez-Martínez LE
Int J Toxicol; 2007; 26(3):237-46. PubMed ID: 17564905
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats].
Zou LL; Li QS; Han GZ; Lü L; Xi H; Li JH
Yao Xue Xue Bao; 2011 Jan; 46(1):75-80. PubMed ID: 21465812
[TBL] [Abstract][Full Text] [Related]
12. Kinetic metabolism of vinpocetine in the rat.
Vereczkey L; Szentirmay Z; Szporny L
Arzneimittelforschung; 1979; 29(6):953-6. PubMed ID: 582790
[TBL] [Abstract][Full Text] [Related]
13. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
Boothe DM; Perkins J
J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
[TBL] [Abstract][Full Text] [Related]
14. Presystemic elimination of the beta-blocker pafenolol in the rat after oral and intraperitoneal administration and identification of a main metabolite in both rats and humans.
Lennernäs H; Renberg L; Hoffmann KJ; Regårdh CG
Drug Metab Dispos; 1993; 21(3):435-40. PubMed ID: 8100498
[TBL] [Abstract][Full Text] [Related]
15. Toxicokinetics and biotransformation of 3-(4-methylbenzylidene)camphor in rats after oral administration.
Völkel W; Colnot T; Schauer UM; Broschard TH; Dekant W
Toxicol Appl Pharmacol; 2006 Oct; 216(2):331-8. PubMed ID: 16806338
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent pharmacokinetics of a new Na+/H+ exchanger inhibitor KR-33028 in rats.
Kim YH; Yoo SD; Kim YS; Lee KH; Lee HS
Biopharm Drug Dispos; 2007 Nov; 28(8):423-9. PubMed ID: 17828714
[TBL] [Abstract][Full Text] [Related]
17. Bioavailabilty and pharmacokinetics of four active alkaloids of traditional Chinese medicine Yanhuanglian in rats following intravenous and oral administration.
Li HL; Zhang WD; Zhang C; Liu RH; Wang XW; Wang XL; Zhu JB; Chen CL
J Pharm Biomed Anal; 2006 Jun; 41(4):1342-6. PubMed ID: 16644173
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs.
Gu Y; Wang GJ; Sun JG; Jia YW; Wang W; Xu MJ; Lv T; Zheng YT; Sai Y
Food Chem Toxicol; 2009 Sep; 47(9):2257-68. PubMed ID: 19524010
[TBL] [Abstract][Full Text] [Related]
19. Biotransformation and pharmacokinetics of the antiplasmodial naphthylisoquinoline alkaloid dioncophylline A.
Sieber M; Dekant W; Faber JH; Bringmann G
Xenobiotica; 2006 Sep; 36(9):750-62. PubMed ID: 16971341
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of 2,3,3,3-tetrafluoropropene (HFO-1234yf).
Schuster P; Bertermann R; Snow TA; Han X; Rusch GM; Jepson GW; Dekant W
Toxicol Appl Pharmacol; 2008 Dec; 233(2):323-32. PubMed ID: 18817801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
